The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and ...

New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or ...

Newseria nie ponosi odpowiedzialności za treści oraz inne materiały (np. infografiki, zdjęcia) przekazywane w „Biurze Prasowym”, których autorami są zarejestrowani użytkownicy tacy jak agencje PR, ...

Scalp psoriasis can run the gamut from mild — with thin scales or plaques that are hardly discernible — to severe, with plaques and scales that cover the scalp, forehead, back of the neck ...

“Although psoriasis plaques are different from plaques in the ... when you have a psoriasis flare or whether the attack will be mild or severe, there are steps you can take to both manage ...

LEO Pharma A/S, a global leader in medical dermatology, today announced the initiation of the phase 2a proof-of-concept DELTA NEXT trial. The trial aims to evaluate the efficacy and safety of ...

Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.

Feb. 3, 2025 — Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal patches and plaques). It affects about 2% of the ...

J&J is hoping to show that the peptide drug can be a more patient-friendly alternative to injectable biologics for plaque psoriasis, including drugs working on IL-23, such as J&J's own Tremfya ...